Ortho-McNeil-Janssen Pharmaceuticals, Inc. v. State

KAREN R. BAKER, Justice.

|,This appeal stems from litigation regarding Risperdal (risperidone). Risper-dal is a second-generation, or atypical, an-tipsychotic medication developed in 1993 by the appellants, Ortho-McNeil-Janssen Pharmaceuticals, Inc. f/k/a Janssen Phar-maceutica, Inc. and/or Janssen, LP, and Johnson & Johnson (“Janssen”). Risper-dal is considered to be highly beneficial in treating schizophrenia patients and allowing them to return to more productive lives.

Risperdal was approved by the Food and Drug Administration (“FDA”) and put on the market in 1994.1 The development of…